Today, Bumrungrad International Hospital Declares it is MERS-Free All Employees under Observation Return Home

Food and Healthcare Press Releases Thursday July 2, 2015 15:03
Bangkok--2 Jul--Bumrungrad International Hospital

Bumrungrad International Hospital announced today that the Department of Disease Control, under the Ministry of Public Health, has allowed all employees under observation at the hospital to return home. Thus, on July 2, 2015, there are no suspected cases of MERS-CoV at Bumrungrad and the hospital is MERS-Free.

The announcement of the first confirmed case of MERS-CoV in Thailand was made on June 18, 2015. Bumrungrad International Hospital was the one to detect the suspected MERS-CoV case and carried out its strict protocols for isolating and preventing the spread of the disease to other staff or patients, and safely transferred the patient for further treatment at the Bamrasnaradura Infectious Diseases Institute under the jurisdiction of the Ministry of Public Health, as per MoPH directions.

Bumrungrad also reported that it will continue to uphold its strict safety measures for the safety of its patients, visitors, employees, and the community. Examples include the Thermo Scan machines that measure body temperature, a Special Screening Clinic, and the addition of Airborne Infection Isolation rooms to screen patients who are in the high-risk group while preventing contamination with other patients; stricter and more frequent disinfection of floors and public equipment; close collaboration with the Department of Disease Control under the Ministry of Public Health to increase measures for monitoring and preventing MERS-CoV; and the management team constantly monitors the situation and meets with experts to adjust plans for dealing with the situation as appropriate.

Bumrungrad's strict protocols that have been practiced continuously has enabled the hospital to handle the situation correctly and quickly, garnering praise from the Ministry of Public Health, the Department of Disease Control, and Department of Health Service Support, and experts from various institutions, including the World Health Organization (WHO) and many news agencies.

Bumrungrad assures you that with the hospital's standard protocols and increased safety measures, meeting and even surpassing the guidelines of the World Health Organization (WHO) and the Central for Disease Control and Prevention (CDC) of the United States, it is confident in its ability to handle situations similar to these now and in the future.


Latest Press Release

Powerful and Proven: Community Health Workers Can Build Health and Equity During Pandemic & Beyond

New Orb Media reporting and data analysis of child mortality rates in 160 countries reveals the versatile and affordable role community health workers (CHWs) play in improving community health. New global model highlights surprising alternatives Orb...

miR Scientific Announces Validation of its Urine Based, Non-Invasive Prostate Cancer Test Published in the Journal of Urology

- Validated Data Reinforces Capability to Molecularly Detect and Characterize Prostate Cancer with Concurrent Sensitivity and Specificity of Over 91% - Data Support Integration of Sentinel Prostate Test(TM) in Patient Care Settings and...

PHC Holdings Corporation and Ascensia Diabetes Care Announce Financing Agreement and Exclusive Global Commercial Agreement With Senseonics

PHC Holdings Corporation and Ascensia Diabetes Care, a PHC Group company, today announced a strategic partnership with Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable...

Global Fund Launches Search for Inspector General

The Global Fund to Fight AIDS, Tuberculosis and Malaria has launched a search for its next Inspector General. A seven-member nomination committee will help the Board of the Global Fund select the next Inspector General. The Board welcomes all candidates...

First liquid biopsy to receive FDA Approval for comprehensive tumor profiling across all solid cancers, Guardant Health's Guardant360(R) CDx, gains credibility among oncologists in Asia, Middle East and Africa.

The U.S. Food and Drug Administration (FDA) has approved Guardant Health's liquid biopsy, Guardant360(R) CDx, for tumor mutation profiling in patients across all solid cancers. For Guardant Health Asia, Middle East and Africa (AMEA), this FDA approval...

Related Topics